Certara, Inc. (CERT)

Market Cap	1.85B
Revenue (ttm)	405.76M
Net Income (ttm)	7.98M
Shares Out	160.62M
EPS (ttm)	0.05
PE Ratio	232.00
Forward PE	23.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,255,896
Open	11.50
Previous Close	11.55
Day's Range	11.45 - 11.87
52-Week Range	8.64 - 15.69
Beta	1.43
Analysts	Buy
Price Target	15.00 (+30.32%)
Earnings Date	Nov 5, 2025

About CERT

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists worki...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,546
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Financial Performance

In 2024, Certara's revenue was $385.15 million, an increase of 8.70% compared to the previous year's $354.34 million. Losses were -$12.05 million, -78.23% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $15.0, which is an increase of 30.32% from the latest price.

Price Target

$15.0

(30.32% upside)

Analyst Consensus: Buy